Atacicept in IgA nephropathy.

IF 4 3区医学 Q2 IMMUNOLOGY

Expert Review of Clinical Immunology Pub Date : 2026-09-01 Epub Date: 2026-09-11 DOI:10.1080/1744666X.2026.2731960

Sheila A Doggrell

引用次数: 0

Abstract

Immunoglobulin A (IgA) nephropathy is a common kidney disease. The cytokines B-cell Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL) have key roles in the pathophysiology of IgA nephropathy. Atacicept is an antibody to BAFF and APRIL. An interim analysis of atacicept in a phase 3 trial in IgA nephropathy, has shown it reduces proteinuria with a good safety profile. This is a very promising finding, and long-term results with atacicept, and a similarly promising BAFF and APRIL inhibitors, telitacicept and povetacicept in nephropathy are eagerly awaited. Of particular interest is whether long-term suppression of immunoglobulins with these inhibitors has adverse effects. Further trials will be needed to determine the respective roles of these inhibitors with angiotensin converting enzyme inhibitors (ACEi) and/or angiotensin receptor blockers (ARBs) and/or sodium-glucose cotransporter 2 (SGLT 2) inhibitors in IgA nephropathy.

查看原文本刊更多论文

阿他塞普在IgA肾病中的作用。

免疫球蛋白A （IgA）肾病是一种常见的肾脏疾病。细胞因子b细胞活化因子（BAFF）和A增殖诱导配体（APRIL）在IgA肾病的病理生理中起关键作用。Atacicept是BAFF和APRIL的抗体。一项针对IgA肾病的3期临床试验的中期分析显示，阿他赛普能减少蛋白尿，且具有良好的安全性。这是一个非常有希望的发现，阿他塞普以及同样有希望的BAFF和APRIL抑制剂，telitacicept和povetacicept在肾病中的长期结果正在热切等待中。特别令人感兴趣的是，用这些抑制剂长期抑制免疫球蛋白是否有不良反应。需要进一步的试验来确定这些抑制剂与血管紧张素转换酶抑制剂（ACEi）和/或血管紧张素受体阻滞剂（ARBs）和/或钠-葡萄糖共转运蛋白2 （SGLT 2）抑制剂在IgA肾病中的各自作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Clinical Immunology IMMUNOLOGY-

CiteScore

7.60

自引率

2.30%

发文量

221

审稿时长

6-12 weeks

期刊介绍： Expert Review of Clinical Immunology (ISSN 1744-666X) provides expert analysis and commentary regarding the performance of new therapeutic and diagnostic modalities in clinical immunology. Members of the International Editorial Advisory Panel of Expert Review of Clinical Immunology are the forefront of their area of expertise. This panel works with our dedicated editorial team to identify the most important and topical review themes and the corresponding expert(s) most appropriate to provide commentary and analysis. All articles are subject to rigorous peer-review, and the finished reviews provide an essential contribution to decision-making in clinical immunology. Articles focus on the following key areas: • Therapeutic overviews of specific immunologic disorders highlighting optimal therapy and prospects for new medicines • Performance and benefits of newly approved therapeutic agents • New diagnostic approaches • Screening and patient stratification • Pharmacoeconomic studies • New therapeutic indications for existing therapies • Adverse effects, occurrence and reduction • Prospects for medicines in late-stage trials approaching regulatory approval • Novel treatment strategies • Epidemiological studies • Commentary and comparison of treatment guidelines Topics include infection and immunity, inflammation, host defense mechanisms, congenital and acquired immunodeficiencies, anaphylaxis and allergy, systemic immune diseases, organ-specific inflammatory diseases, transplantation immunology, endocrinology and diabetes, cancer immunology, neuroimmunology and hematological diseases.